Ranson, Marie

Top Publications

Year	Title
2019	Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma Published in Journal of Investigative Dermatology
2018	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer Published in Journal of Medicinal Chemistry
2017	SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer Published in Oncogene
2017	The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis Published in Oncotarget
2008	Revisiting the biological roles of PAI2 (SERPINB2) in cancer Published in Nature Reviews Cancer
2007	A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells Published in Biochemical Journal

Research Areas

Research Overview

Professor Marie Ranson received her PhD from the University of Sydney (1990). After a post-doctoral Fellowship at the National Institutes of Health in Bethesda MD, USA she obtained a Research Fellowship and then a tenured teaching and research academic position in the School of Biological Sciences at the University of Wollongong. Marie is also the Illawarra Lead and executive member of the Cancer Institute NSW funded CONCERT Translational Cancer Research Centre. Her main area of expertise is in molecular biomarkers of metastasis and she is recognised
internationally for her contributions to the field of the urokinase plasminogen activation system (PAS), particularly in solid tumour biology. Combined with her extensive experience with in vitro, ex vivo and animal tumour models, she has also successfully led and/or contributed IP to several drug development projects related, but not limited, to this field. She has supervised 16 PhD, 4 MSc and 35 Honours students to completion to date and was a past recipient of the University of Wollongong Vice-Chancellor’s Award for Excellence in Research Supervision.

Key current research areas:
- The plasminogen activation system in tumour invasion and metastasis.
- Genomic and expression analyses for the identification of biomarkers to predict cancer progression and responsiveness to single and combinatorial drug treatment using patient derived culture and animal models.
- Targeted drug development programmes against biomarkers of cancer and inflammation
- Molecular Horizons
- Illawarra Health and Medical Research Institute
- Centre for Oncology Education & Research Translation
- Cancer Drug Discovery Group
- Proteostasis and Disease Research Centre

Head Of

Cancer Cell and Molecular Biology Group leader 2009 -

Member Of

Molecular Horizons member 2019 -
The Centre for Oncology Education and Research Translation (CONCERT) Deputy Director 2014 -
International Society of Fibrinolysis and Proteolysis
Metastasis Research Society
The American Society for Biochemistry and Molecular Biology

Has Collaborator

Aghmesheh, Morteza Person
Ashford, Bruce Dr
Kelso, Michael Professor
Perrow, Kara Dr

Clinical Activities

Deflexifol Phase 1 trial Scientific advisor 2014 -

Selected Publications

Journal Article

Year	Title
2022	A Novel Role for Plasminogen Activator Inhibitor Type-2 as a Hypochlorite-Resistant Serine Protease Inhibitor and Holdase Chaperone Published In Cells
2022	A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic review) Published In Discover Oncology
2022	Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma Published In Frontiers in Oncology
2022	Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA) Published In Journal of Medicinal Chemistry
2022	High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma. Published In Clinical cancer research : an official journal of the American Association for Cancer Research
2022	The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets Published In Biomolecules
2022	Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity Published In Biophysical Reviews
2022	Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma Published In Frontiers in Oncology
2021	Demystifying emerging bulk RNA-Seq applications: the application and utility of bioinformatic methodology Published In Briefings in bioinformatics
2021	Experimental and clinical evidence supports the use of urokinase plasminogen activation system components as clinically relevant biomarkers in gastroesophageal adenocarcinoma Published In Cancers
2021	Gene expression profiling of perineural invasion in head and neck cutaneous squamous cell carcinoma Published In Scientific Reports
2021	Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation Published In Science Advances
2021	P-115 The potential of panel-based gene expression analysis in the identification of head and neck cutaneous squamous cell carcinoma with high risk of lymph node metastasis Published In Oral Oncology
2021	Roles of the na⁺/h⁺ exchanger isoform 1 and urokinase in prostate cancer cell migration and invasion Published In International Journal of Molecular Sciences
2021	Screening of 5- and 6-substituted amiloride libraries identifies dual-UPA/NHE1 active and single target-selective inhibitors Published In International Journal of Molecular Sciences
2021	Systematic evaluation of structure–property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride Published In Bioorganic and Medicinal Chemistry
2021	Targeting the urokinase plasminogen activator (uPA) pathway inhibits pancreatic cancer progression Published In Pancreatology
2020	Assessing the role of pharyngeal cell surface glycans in group a streptococcus biofilm formation Published In Antibiotics
2020	Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides Published In Cancers
2020	Comprehensive mutational and phenotypic characterization of new metastatic cutaneous squamous cell carcinoma cell lines reveal novel drug susceptibilities Published In International Journal of Molecular Sciences
2020	Design, synthesis and evaluation of carbamate-linked uridyl-based inhibitors of human ST6Gal I Published In Bioorganic and Medicinal Chemistry
2020	Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer Published In Scientific Reports
2020	Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress Published In Research and Practice in Thrombosis and Haemostasis
2020	N-alkylisatin-loaded liposomes target the urokinase plasminogen activator system in breast cancer Published In Pharmaceutics
2020	Thulium oxide nanoparticles as radioenhancers for the treatment of metastatic cutaneous squamous cell carcinoma Published In Physics in Medicine and Biology
2019	6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease Published In Bioorganic and Medicinal Chemistry Letters
2019	Characterizing the role of tissue-type plasminogen activator in a mouse model of Group A streptococcal infection Published In Microbes and Infection: a journal on infectious agents and host defenses
2019	Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma Published In Pathology
2019	First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment Published In Asia Pacific Journal of Clinical Oncology
2019	Human pregnancy zone protein stabilizes misfoldedproteins including preeclampsia- and Alzheimer’s-associated amyloid beta peptide Published In Proceedings of the National Academy of Sciences of USA
2019	Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies? Published In Journal of Clinical Pathology
2019	Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma Published In Journal of Investigative Dermatology
2019	Paracrine recruitment and activation of fibroblasts by c-Myc expressing breast epithelial cells through the IGFs/IGF-1R axis Published In International Journal of Cancer
2019	The urokinase plasminogen activation system in rheumatoid arthritis: Pathophysiological roles and prospective therapeutic targets Published In Current Drug Targets
2018	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer Published In Journal of Medicinal Chemistry
2018	Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma Published In Modern Pathology
2018	Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer Published In World Journal of Gastroenterology
2018	Quantification of ligand density and stoichiometry on the surface of liposomes using single-molecule fluorescence imaging Published In Journal of Controlled Release
2018	Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Published In Clinical Colorectal Cancer
2018	Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities Published In Journal of Controlled Release
2017	A first look at the genomic landscape of non-metastatic cutaneous squamous cell carcinoma Published In Pathology
2017	Amorphous protein aggregates stimulate plasminogen activation, leading to release of cytotoxic fragments that are clients for extracellular chaperones Published In Journal of Biological Chemistry
2017	Deflexifol (a novel formulation of 5FU): Pharmacokinetics in a phase 1 trial in comparison to 5FU. Published In Journal of Clinical Oncology
2017	Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment. Published In Journal of Clinical Oncology
2017	PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma Published In Pathology
2017	Phase 1 study of infusional or bolus deflexifol (a novel formulation of 5FU, folinic acid, and cyclodextrin) after failure of standard treatment. Published In Journal of Clinical Oncology
2017	Probing the pharmacokinetics of cucurbit[7, 8 and 10]uril: and a dinuclear ruthenium antimicrobial complex encapsulated in cucurbit[10]uril Published In Organic and Biomolecular Chemistry
2017	RNA sequencing of metastatic cutaneous SCC with nano-string: preliminary results Published In Pathology
2017	Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets Published In Head and Neck
2017	SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer Published In Oncogene
2017	Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients Published In BMC Cancer
2017	The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis Published In Oncotarget
2017	p16 expression in cutaneous squamous cell carcinoma (cSCC) of the head and neck Published In Pathology
2017	p16 expression in cutaneous squamous cell carcinoma of the head and neck is not associated with integration of high risk HPV DNA or prognosis Published In Pathology
2016	5′-substituted amiloride derivatives as allosteric modulators binding in the sodium ion pocket of the adenosine A_2A receptor Published In Journal of Medicinal Chemistry
2016	A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Published In Investigational new drugs
2016	A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2016	Circulating tumour cells in regionally metastatic cutaneous squamous cell carcinoma: a pilot study Published In Oncotarget
2016	Gastric cancer stem cells: evidence, potential markers, and clinical implications Published In Journal of Gastroenterology
2016	N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell lines Published In Heliyon
2016	PZP and PAI-2: structurally-diverse, functionally similar pregnancy proteins? Published In The International Journal of Biochemistry and Cell Biology
2016	Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors Published In Bioorganic and Medicinal Chemistry Letters
2015	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. Published In Investigational new drugs
2015	Erratum to: Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery Published In Pharmaceutical Research
2015	HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer Published In Oncoscience
2015	Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery Published In Pharmaceutical Research
2015	Selecting Australian marine macroalgae based on the fatty acid composition and anti-inflammatory activity Published In Journal of Applied Phycology
2015	Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers Published In Cancer Research
2015	SerpinB2 (PAI-2) modulates proteostasis via binding misfolded proteins and promotion of cytoprotective inclusion formation Published In PLoS One
2015	Therapeutic drug monitoring for cancer patients receiving chemotherapy Published In Asia Pacific Journal of Clinical Oncology
2014	Fgfr Inhibitor and Chemotherapy in Gastric Cancer (Facing): Phase I Results from an Ecmc Combinations Alliance Phase I/II Trial of Azd4547 in Combination with Cisplatin and Capecitabine (Cx) Published In Annals of Oncology
2014	Plasmin(ogen) acquisition by group A Streptococcus protects against C3b-mediated neutrophil killing Published In Journal of Innate Immunity
2014	Preliminary Azd9291 Western and Asian Clinical Pharmacokinetics (Pk) in Patients (Pts) and Healthy Volunteers (Hv): Implications for Formulation, Dose and Dosing Frequency in Pivotal Clinical Studies Published In Annals of Oncology
2014	Updated Safety and Efficacy from a Phase I Study of Azd9291 in Patients (Pts) with Egfr-Tki-Resistant Non-Small Cell Lung Cancer (Nsclc) Published In Annals of Oncology
2013	A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection Published In PLoS Pathogens
2013	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. Published In British journal of cancer
2013	Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communication. Published In Journal of pharmaceutical and biomedical analysis
2013	Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice Published In Anticancer Research: international journal of cancer research and treatment
2013	The antiangiogenic properties of sulfated β-cyclodextrins in anticancer formulations incorporating 5-fluorouracil Published In Anti-Cancer Drugs: international journal on anti-cancer agents
2012	32 Circulating Tumour Cells, Utility Beyond Prognosis? Published In European Journal of Cancer
2012	610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma Published In European Journal of Cancer
2012	613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors Published In European Journal of Cancer
2012	Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor Published In Cancer Letters
2012	Bacterial plasminogen receptors: mediators of a multifaceted relationship Published In BioMed Research International
2012	ChemInform Abstract: Synthesis and Preliminary Evaluation of Amiloride Analogues as Inhibitors of the Urokinase‐Type Plasminogen Activator (uPA). Published In ChemInform
2012	Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms Published In Nuclear Medicine and Biology
2012	Gelapin, a degradable genipin cross-linked gelatin hydrogel Published In RSC Advances: an international journal to further the chemical sciences
2012	Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2012	Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Published In British journal of cancer
2012	Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Published In British journal of cancer
2012	Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2- diones, pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives Published In Tetrahedron: the international journal for the rapid publication of full original research papers and critical reviews in organic chemistr
2012	Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-Alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth Published In Current Cancer Drug Targets
2011	Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty? Published In International Journal of Cancer
2011	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Published In British journal of cancer
2011	Dependence on Endocytic Receptor Binding via a Minimal Binding Motif Underlies the Differential Prognostic Profiles of SerpinE1 and SerpinB2 in Cancer Published In Journal of Biological Chemistry
2011	Editorial: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy Published In Current Drug Targets
2011	Forty Years Later and the Role of Plasminogen Activator Inhibitor Type 2/SERPINB2 Is Still an Enigma Published In Seminars in Thrombosis and Hemostasis
2011	In vivo pharmacokinetics of radioiodinated urokinase plasminogen activator (UPA) inhibitors for imaging metastatic cancer Published In Internal Medicine Journal
2011	Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: implications for cellular proteolysis and adhesion in cancer Published In Cancer Letters
2011	Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2011	Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles Published In Anti-Cancer Drugs: international journal on anti-cancer agents
2011	Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand Published In Bioorganic and Medicinal Chemistry
2011	Synthesis and hydrolytic evaluation of acid-labile imine-linked cytoxic isatin model systems Published In Bioorganic and Medicinal Chemistry
2011	Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA) Published In Bioorganic and Medicinal Chemistry Letters
2010	A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. Published In Journal of Clinical Oncology
2010	A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. Published In British journal of cancer
2010	Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). Published In Journal of Clinical Oncology
2010	Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Published In The HUGO journal
2010	Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes Published In Thrombosis and Haemostasis
2010	Effects on human plasminogen conformation and activation rate caused by interaction with VEK-30, a peptide derived from the group A streptococcal M-like protein (PAM) Published In BBA: Proteins and Proteomics
2010	Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2010	P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells Published In BBA: General Subjects
2010	Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer. Published In International journal of clinical pharmacology and therapeutics
2010	Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2010	Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro Published In Bioorganic and Medicinal Chemistry Letters
2010	SerpinB2 Published In AfCS-Nature Molecule Pages
2009	A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Published In Cancer chemotherapy and pharmacology
2009	A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Published In British journal of cancer
2009	Conformational rearrangements of plasminogen activator inhibitor type 2 Published In Cellular and Molecular Life Sciences
2009	Cytotoxic and anticancer activities of Isatin and its derivatives: a comprehensive review from 2000-2008 Published In Anti-Cancer Agents in Medicinal Chemistry
2009	Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Published In British journal of cancer
2009	Detection of EGFR and KRAS mutations in circulating free DNA in patients with operable non small cell lung cancer (NSCLC) Published In Lung Cancer
2009	Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate Published In Anti-Cancer Drugs: international journal on anti-cancer agents
2009	Erratum: A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer Published In British Journal of Cancer
2009	Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): A novel paradigm in clinical drug development Published In Journal of Clinical Oncology
2009	O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Published In British journal of cancer
2009	PH-triggered release of potent isatin-derived cytotoxins conjugated to the tumour targeting protein PAI-2 Published In Annals of Oncology
2009	Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies Published In Journal of Clinical Oncology
2009	Synthesis and in vitro anticancer activity of a targeted plasminogen activator inhabitator type II (PAI-2) cytotoxin conjugate Published In Annals of Oncology
2009	Synthesis and in vitro anticancer activity of a targeted plasminogen activator inhibitor type II (PAI-2) cytotoxin conjugate Published In Annals of Oncology
2009	The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity Published In BMC Biotechnology
2008	364 POSTER Obatoclax in SCLC: preclincal evaluation of a BH3 mimetic Published In European Journal of Cancer Supplements
2008	A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours Published In Journal of Clinical Oncology
2008	A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients Published In Journal of Clinical Oncology
2008	A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Published In British journal of cancer
2008	Allelic variants of strepokinase from Streptococcus pyogenes display functional differences in plasminogen activation Published In The FASEB Journal
2008	Biomarker method validation in anticancer drug development. Published In British journal of pharmacology
2008	Biomarkers of apoptosis. Published In British journal of cancer
2008	First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin Published In Journal of Clinical Oncology
2008	N-Phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents Published In Bioorganic and Medicinal Chemistry
2008	Optimisation of circulating biomarkers of cell death for routine clinical use. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2008	Peptides and small molecules targeting the plasminogen activation system: Towards prophylactic anti-metastasis drugs for breast cancer Published In Recent Patents on Anti-Cancer Drug Discovery
2008	Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions Published In Thrombosis and Haemostasis
2008	Revisiting the biological roles of PAI2 (SERPINB2) in cancer Published In Nature Reviews Cancer
2007	6587 POSTER A phase IB, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 study Published In European Journal of Cancer Supplements
2007	A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells Published In Biochemical Journal
2007	An investigation into the Cytotoxicity and mode of action of some Novel N-Alkyl-Substituted Isatins Published In Journal of Medicinal Chemistry
2007	Corrigendum to "In vitro cytotoxicity evaluation of some substituted isatin derivatives" [Bioorg. Med. Chem. 15 (2007) 931-938] (DOI:10.1016/j.bmc.2006.10.035) Published In Bioorganic and Medicinal Chemistry
2007	Final results of a phase I clinical trial of the bioreductive drug RH1 Published In Journal of Clinical Oncology
2007	IAPs as a target for anticancer therapy. Published In Current cancer drug targets
2007	In vitro cytotoxicity evaluation of some substituted isatin derivatives Published In Bioorganic and Medicinal Chemistry
2007	P59 Building a quality assurance (QA) system that is fit for purpose in an academic laboratory Published In European Journal of Cancer Supplements
2007	Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity Published In Breast Cancer Research
2007	Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma Published In Molecular Cancer Therapeutics
2007	Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Published In Cancer chemotherapy and pharmacology
2007	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2007	The plasminogen-binding group A streptococcal M protein-related protein Prp binds plasminogen via arginine and histidine residues Published In Journal of Bacteriology
2007	Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial. Published In Cancer chemotherapy and pharmacology
2006	143 POSTER Comparison of cell death ELISAs applied as potential surrogate biomarkers in the clinical evalution of AEG35156 (XIAP antisense) Published In European Journal of Cancer Supplements
2006	221 A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma Published In Lung Cancer
2006	427 POSTER Preclinical development of xiapuradamib therapy for lung cancer Published In European Journal of Cancer Supplements
2006	A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors Published In Journal of Clinical Oncology
2006	A structural basis for differential cell signaling initiated by PAI-1 and PAI-2: Implications for Metastatic Potential Published In JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2006	Assessment of known/potential binding sites in the PAI-2 CD-loop for interaction with annexin II and endocytosis receptors Published In JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2006	Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Published In British journal of cancer
2006	Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Published In British journal of cancer
2006	SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study Published In Journal of Clinical Oncology
2006	The maintenance of high affinity plasminogen binding by PAM variants from group A streptococci is mediated by both a1 and a2 repeat domains and is not dependent on lysine residues Published In JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2006	ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial Published In Journal of Clinical Oncology
2005	A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. Published In European journal of cancer (Oxford, England : 1990)
2005	O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study Published In Lung Cancer
2005	Targeted antitumour therapy--future perspectives. Published In British journal of cancer
2005	The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results Published In Journal of Clinical Oncology
2005	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Published In British journal of cancer
2005	Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Published In British journal of cancer
2004	453 Validation of pharmacodynamic assays to determine the clinical effect of an antisense to the XIAP inhibitor of apoptosis Published In European Journal of Cancer Supplements
2004	494 Preliminary results from a phase I clinical trial of the bioreductive drug, RH1 Published In European Journal of Cancer Supplements
2004	A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus Published In Journal of Clinical Oncology
2004	A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus Published In Journal of Clinical Oncology
2004	Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC) Published In Journal of Clinical Oncology
2004	Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC) Published In Journal of Clinical Oncology
2004	DT-diaphorase: a target for new anticancer drugs. Published In Cancer treatment reviews
2004	Epidermal growth factor receptor tyrosine kinase inhibitors. Published In British journal of cancer
2004	Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Published In British journal of cancer
2003	Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Published In Lung cancer (Amsterdam, Netherlands)
2003	Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. Published In Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2002	Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Published In Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2001	56. In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2 Published In Nuclear Medicine Communications
2001	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Published In British journal of cancer
2001	Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Published In Critical reviews in oncology/hematology
2001	Characterisation of co-polymer targeting of doxorubicin and its iodinated conjugate in tumour models Published In Journal of Labelled Compounds and Radiopharmaceuticals
2001	PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study Published In European Journal of Cancer
2001	Preparation of an I‐124 labelled doxorubicin conjugate for in vivo assessment of polymer targeted anticancer therapy Published In Journal of Labelled Compounds and Radiopharmaceuticals
2000	A possible mechanism for the enhanced activation of plasminogen on malignant breast cancer cells Published In Fibrinolysis and Proteolysis
2000	Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours. Published In British journal of cancer
2000	Phase II study of Exatecan Mesylate (DX-8951f) in advanced NSCLC Published In Lung Cancer
2000	Phase II study of oral topotecan in advanced non-small cell lung cancer. Published In Clinical cancer research : an official journal of the American Association for Cancer Research
2000	Plasminogen binding and activation during late-stage cell death Published In Fibrinolysis and Proteolysis
2000	Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1999	Phase II study results on safety and efficacy of CAELYX® (DOXIL®) in combination with paclitaxel in the treatment of metastatic breast cancer Published In European Journal of Cancer
1998	Increased plasminogen binding is associated with metastatic breast cancer cells: Differential expression of plasminogen binding proteins Published In British Journal of Cancer
1998	Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control and tumour xenograft-bearing mice Published In Fibrinolysis and Proteolysis
1998	Rapid auto-catalytic processing of Gluplasminogen occurs on malignant breast cancer cell-surfaces Published In Fibrinolysis and Proteolysis
1997	195 Lysine-dependant Glu-Plasminogen binding to α-enolase induces conformational changes resulting in higher affinity interactions Published In Fibrinolysis and Proteolysis
1997	197 Do plasminogen receptors play a role in breast cancer malignancy? Published In Fibrinolysis and Proteolysis
1997	Central venous catheter placement: extending the role of the nurse. Published In Journal of the Royal College of Physicians of London
1997	Do plasminogen receptors play a role in breast cancer malignancy? Published In Fibrinolysis and Proteolysis
1997	Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Published In Seminars in oncology
1997	Lysine-dependant glu-plasminogen binding to a-enolase induces conformational changes resulting in higher affinity interactions Published In Fibrinolysis and Proteolysis
1997	Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma Published In EUROPEAN JOURNAL OF CANCER
1997	Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. Published In European journal of cancer (Oxford, England : 1990)
1997	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Published In European journal of cancer (Oxford, England : 1990)
1997	Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. Published In Seminars in oncology
1997	The human ENO1 gene product (recombinant human α-enolase) displays characteristics required for a plasminogen binding protein Published In Biochimica et Biophysica Acta - Protein Structure and Molecular Enzymology
1997	Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. Published In Journal of clinical oncology : official journal of the American Society of Clinical Oncology
1996	A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1996	Liposomal drug delivery. Published In Cancer treatment reviews
1995	1058 A phase II evaluation of bone marrow protection by ethyol® (Amifostine)(Am) in patients with non-small cell lung cancer (NSCLC) treated with carboplatin(c) Published In European Journal of Cancer
1995	Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Published In British journal of cancer
1995	Chemotherapy in non-small cell lung cancer. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1995	Gnot1, a member of a new homeobox gene subfamily, is expressed in a dynamic, region-specific domain along the proximodistal axis of the developing limb Published In Mechanisms of Development
1995	The importance of dose and schedule in chemotherapy for small cell lung cancer. Published In Anti-cancer drugs
1995	The organizer-associated chick homeobox gene, Gnot1, is expressed before gastrulation and regulated synergistically by activin and retinoic acid Published In Developmental Biology
1995	VAD chemotherapy as remission induction for multiple myeloma. Published In British journal of cancer
1994	A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer. Published In British journal of cancer
1994	Acute lymphoblastic leukaemia following Hodgkin's disease is associated with a good prognosis. Published In British journal of haematology
1994	Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1994	Effects of estrogens on human melanocytes in vitro Published In Journal of Steroid Biochemistry and Molecular Biology
1994	Population and Bayesian pharmacokinetics in oncology. Published In Clinical oncology (Royal College of Radiologists (Great Britain))
1994	Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresis. Published In Bone marrow transplantation
1994	Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1993	A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1993	Cutaneous infection with Rhizopus oryzae and Aspergillus niger following bone marrow transplantation. Published In The Journal of hospital infection
1993	Selection of optimal intensive induction chemotherapy preceding high-dose consolidation chemotherapy for advanced breast cancer and investigation of the optimal time for peripheral blood progenitor cell (PBSC) collection Published In The Breast
1992	Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma. Published In European journal of cancer (Oxford, England : 1990)
1991	An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1991	Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. Published In Journal of clinical oncology : official journal of the American Society of Clinical Oncology
1991	Post consolidation therapy for adult patients with acute myeloid leukaemia. Published In British journal of haematology
1990	Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients. Published In The Journal of hospital infection
1990	Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1990	Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. Published In European journal of cancer (Oxford, England : 1990)
1988	Extracellular matrix modulates the function of human melanocytes but not melanoma cells Published In Journal of Cellular Physiology
1988	Human melanocytes as a target tissue for hormones: In vitro studies with 1α-25, dihydroxyvitamin D3, α-melanocyte stimulating hormone, and beta-estradiol Published In Journal of Investigative Dermatology
1988	Human melanoma cells: Functional modulation by calciotropic hormones Published In Journal of Investigative Dermatology

Chapter

Year	Title
2010	Inhibitors of the Plasminogen Activation System - Promising New Agents for Suppressing Breat Cancer Metastasis Published In Frontiers in Anti-Cancer Drug Discovery
2007	Gene expression and tagging of Streptococcal proteins Published In Molecular Biology of Streptococci Publisher Wymondham

Conference Paper

Year	Title
2021	Improving delivery of amiloride analogues as uPA selective inhibitors for use in metastatic disease Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	Inhibition of focal adhesion kinase in cutaneous squamous cell carcinoma Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	Non-coding and coding genomic mutational drivers of metastatic cutaneous squamous cell carcinoma Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	Targeting the Urokinase Plasminogen Activator Pathway in Combination With Chemotherapy Inhibits Pancreatic Cancer Progression Published In PANCREAS
2021	Targeting the urokinase plasminogen activator pathway inhibits pancreatic cancer progression Published In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
2021	The potential of panel-based gene expression analysis in the identification of head and neck cutaneous squamous cell carcinoma with high risk of lymph node metastasis Published In ORAL ONCOLOGY
2021	The role of urokinase plasminogen activator receptor in HNcSCC progression and metastasis Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	Tracking circulating tumour DNA in patients with resectable gastroesophageal cancer Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	cMet signalling affects the invasive capacity of a gastric cancer cell circulating tumour cell line Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2018	Amiloride Analogues as Inhibitors of Human Urokinase Plasminogen Activator and Anti-Pancreatic Cancer Agents Published In PANCREAS
2018	Cancer stem cell markers in metastatic gastroesophageal adenocarcinoma Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2018	Comparison of Clinically Relevant Somatic Mutations in Primary and Metastatic Head and Neck Cutaneous Squamous Cell Carcinoma Published In MODERN PATHOLOGY
2018	Drug and radio sensitivity profile of a primary CTC cell line derived from a patient with metastatic neuroendocrine tumour of the distal oesophagus Published In ESMO Open
2018	Impact of rural and remoteness on overall survival in Australian patients with stage I-III colorectal cancer Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2018	Somatic Mutations in Head and Neck Cutaneous Squamous Cell Carcinoma Published In MODERN PATHOLOGY
2017	A First Look at the Genomic Landscape of Non-Metastatic Cutaneous Squamous Cell Carcinoma Published In LABORATORY INVESTIGATION
2017	PD-L1 Expression Predicts Improved Disease Free Survival in High Risk Head and Neck Cutaneous Squamous Cell Carcinoma Published In LABORATORY INVESTIGATION
2017	p16 Expression in Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck Published In LABORATORY INVESTIGATION
2016	Adjuvant chemotherapy for stage III colorectal cancer in the elderly Published In ANNALS OF ONCOLOGY
2016	BIOBANKING AT A REGIONAL TERTIARY HOSPITAL: AN INITIAL EXPERIENCE AND IDENTIFICATION OF BARRIERS TO PATIENT CONSENT Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2016	EXPRESSION OF UROKINASE PLASMINOGEN ACTIVATION SYSTEM IN PRIMARY GASTRO-ESOPHAGEAL ADENOCARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2016	PHARMACOKINETICS OF A NOVEL FORMULATION OF 5-FLUOROURACIL (5FU) AND LEUCOVORIN (LV): (DEFLEXIFOL) IN A PHASE I TRIAL Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2011	Selective Release of Potent N-Alkylisatin Based Cytotoxins via Hydrolysis of pH Sensitive Imine Linkers Published In 27th International Symposium on the Chemistry of Natural Products and the 7th International Conference on Biodiversity (ISCNP-27 & ICOB-7)
2010	Selective release of potent N-alkylisatin based cytotoxins via hydrolysis of pH sensitive imine linkers Published In 2010 International Chemical Congress of Pacific Basin Societies
2007	The pharmacokinetic and tolerability profile of once-daily oral ZD4054 in Japanese and Caucasian patients with hormone-refractory prostate cancer Published In EJC SUPPLEMENTS
2001	In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labeled-plasminogen activator inhibitor type 2 Published In EUROPEAN JOURNAL OF NUCLEAR MEDICINE
1993	Limb-type differences in expression domains of certain chick Hox-4 genes and relationship to pattern modification for flight. Published In Progress in clinical and biological research

Investigator On

Year	Title
2020 - 2023	Cutaneous Squamous Cell Carcinoma: defining prognostic markers of metastasis Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Ideas Grant
2014 - 2021	Centre for Oncology Education and Research Translation (CONCERT) Awarded by: Cancer Institute NSW Funding Scheme: Translational Cancer Research Centre
2020	Reducing the Morbidity of Head and Neck Cancer Treatment Awarded by: Cancer Institute NSW Funding Scheme: Translational Program Grant (TPG)
2016 - 2019	Repurposing Amiloride into Breast Cancer Drugs with a Dual-Targeting Mechanism Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Project Grant
2014	COUNTESS 11 FL Cell Counter and Qubit Quant Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2013	Neon Transfection System: Workstation for transfer of genetic material into hard-to-work-with cells Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2012	Optimisation of PAI-2 forms for non-invasive PET imaging of malignant tumours Awarded by: Australian Institute of Nuclear Science and Engineering (AINSE) Funding Scheme: Research Awards
2011	Regional facility for macomolecular X-ray crystallography Awarded by: Australian Research Council (ARC) Funding Scheme: Linkage Infrastructure Equipment & Facilities (LIEF)
2009	Regional facility for real time analysis of molecular interactions Awarded by: Australian Research Council (ARC) Funding Scheme: Linkage Infrastructure Equipment & Facilities (LIEF)
2008	Optimised delivery of chemotherapy for solid tumours Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Development Grant
2007	Avestin EmulsiFlex TM-C5 Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2007	Unified model for group A streptococcal invasive disease initiation Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Project Grant
	Contributions to Leica Dmi8 microscope Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
	GoBlot machines and Leica Objective Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
	Lumenera Infinity 2-5 microscope colour camera Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
	Novel uPA-targeting small molecules for the treatment of rheumatoid arthritis Awarded by: Arthritis Australia Funding Scheme: Grant-in-Aid
	Unravelling genetic markers of progression and metastases in head and neck cutaneous squamous cell carcinoma Awarded by: Australian and New Zealand Head and Neck Cancer Society Research Foundation Funding Scheme: Research Grant

Potential Supervision Topics

Cutaneous Squamous Cell Carcinoma: Defining Prognostic Markers of Metastasis

Advisees

Graduate Advising Relationship

Degree	Research Title	Advisee
Doctor of Philosophy	Bismuth-NSAIDs as Colorectal Cancer Chemopreventatives	Oliver, Tara
Doctor of Philosophy	Investigations of the roles of pregnancy zone protein (PZP) and plasminogen activator inhibitor type-2 (PAl-2) in extracellular proteostasis	Cater, Jordan
Doctor of Philosophy	Pharmacological Profiling of Amiloride Analogues as Inhibitors of the Urokinase Plasminogen Activation System in Pancreatic Ductal Adenocarcinoma	Kumar, Ashna
Doctor of Philosophy	Molecular and Clinical Biomarker assessment of gastric cancer	Tincknell, Gary
Doctor of Philosophy	Metastatic cutaneous squamous cell carcinoma (cSCC): development of 3- dimensional patient-derived cultures for functional genomics and drug response profiling.	Genenger, Benjamin
Doctor of Philosophy	Localized delivery of chemotherapy and Immunotherapy for Triple-negative breast cancer.	Minaei, Elahe

Web Of Science Researcher Id

A-6324-2008

Scopus Id

7005465112

Top Publications

Year	Title
2019	Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma Published in Journal of Investigative Dermatology
2018	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer Published in Journal of Medicinal Chemistry
2017	SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer Published in Oncogene
2017	The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis Published in Oncotarget
2008	Revisiting the biological roles of PAI2 (SERPINB2) in cancer Published in Nature Reviews Cancer
2007	A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells Published in Biochemical Journal

Research Areas

Research Overview

Professor Marie Ranson received her PhD from the University of Sydney (1990). After a post-doctoral Fellowship at the National Institutes of Health in Bethesda MD, USA she obtained a Research Fellowship and then a tenured teaching and research academic position in the School of Biological Sciences at the University of Wollongong. Marie is also the Illawarra Lead and executive member of the Cancer Institute NSW funded CONCERT Translational Cancer Research Centre. Her main area of expertise is in molecular biomarkers of metastasis and she is recognised
internationally for her contributions to the field of the urokinase plasminogen activation system (PAS), particularly in solid tumour biology. Combined with her extensive experience with in vitro, ex vivo and animal tumour models, she has also successfully led and/or contributed IP to several drug development projects related, but not limited, to this field. She has supervised 16 PhD, 4 MSc and 35 Honours students to completion to date and was a past recipient of the University of Wollongong Vice-Chancellor’s Award for Excellence in Research Supervision.

Key current research areas:
- The plasminogen activation system in tumour invasion and metastasis.
- Genomic and expression analyses for the identification of biomarkers to predict cancer progression and responsiveness to single and combinatorial drug treatment using patient derived culture and animal models.
- Targeted drug development programmes against biomarkers of cancer and inflammation
- Molecular Horizons
- Illawarra Health and Medical Research Institute
- Centre for Oncology Education & Research Translation
- Cancer Drug Discovery Group
- Proteostasis and Disease Research Centre

Head Of

Cancer Cell and Molecular Biology Group leader 2009 -

Member Of

Molecular Horizons member 2019 -
The Centre for Oncology Education and Research Translation (CONCERT) Deputy Director 2014 -
International Society of Fibrinolysis and Proteolysis
Metastasis Research Society
The American Society for Biochemistry and Molecular Biology

Has Collaborator

Aghmesheh, Morteza Person
Ashford, Bruce Dr
Kelso, Michael Professor
Perrow, Kara Dr

Clinical Activities

Deflexifol Phase 1 trial Scientific advisor 2014 -

Selected Publications

Journal Article

Year	Title
2022	A Novel Role for Plasminogen Activator Inhibitor Type-2 as a Hypochlorite-Resistant Serine Protease Inhibitor and Holdase Chaperone Published In Cells
2022	A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic review) Published In Discover Oncology
2022	Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma Published In Frontiers in Oncology
2022	Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA) Published In Journal of Medicinal Chemistry
2022	High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma. Published In Clinical cancer research : an official journal of the American Association for Cancer Research
2022	The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets Published In Biomolecules
2022	Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity Published In Biophysical Reviews
2022	Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma Published In Frontiers in Oncology
2021	Demystifying emerging bulk RNA-Seq applications: the application and utility of bioinformatic methodology Published In Briefings in bioinformatics
2021	Experimental and clinical evidence supports the use of urokinase plasminogen activation system components as clinically relevant biomarkers in gastroesophageal adenocarcinoma Published In Cancers
2021	Gene expression profiling of perineural invasion in head and neck cutaneous squamous cell carcinoma Published In Scientific Reports
2021	Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation Published In Science Advances
2021	P-115 The potential of panel-based gene expression analysis in the identification of head and neck cutaneous squamous cell carcinoma with high risk of lymph node metastasis Published In Oral Oncology
2021	Roles of the na⁺/h⁺ exchanger isoform 1 and urokinase in prostate cancer cell migration and invasion Published In International Journal of Molecular Sciences
2021	Screening of 5- and 6-substituted amiloride libraries identifies dual-UPA/NHE1 active and single target-selective inhibitors Published In International Journal of Molecular Sciences
2021	Systematic evaluation of structure–property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride Published In Bioorganic and Medicinal Chemistry
2021	Targeting the urokinase plasminogen activator (uPA) pathway inhibits pancreatic cancer progression Published In Pancreatology
2020	Assessing the role of pharyngeal cell surface glycans in group a streptococcus biofilm formation Published In Antibiotics
2020	Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides Published In Cancers
2020	Comprehensive mutational and phenotypic characterization of new metastatic cutaneous squamous cell carcinoma cell lines reveal novel drug susceptibilities Published In International Journal of Molecular Sciences
2020	Design, synthesis and evaluation of carbamate-linked uridyl-based inhibitors of human ST6Gal I Published In Bioorganic and Medicinal Chemistry
2020	Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer Published In Scientific Reports
2020	Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress Published In Research and Practice in Thrombosis and Haemostasis
2020	N-alkylisatin-loaded liposomes target the urokinase plasminogen activator system in breast cancer Published In Pharmaceutics
2020	Thulium oxide nanoparticles as radioenhancers for the treatment of metastatic cutaneous squamous cell carcinoma Published In Physics in Medicine and Biology
2019	6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease Published In Bioorganic and Medicinal Chemistry Letters
2019	Characterizing the role of tissue-type plasminogen activator in a mouse model of Group A streptococcal infection Published In Microbes and Infection: a journal on infectious agents and host defenses
2019	Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma Published In Pathology
2019	First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment Published In Asia Pacific Journal of Clinical Oncology
2019	Human pregnancy zone protein stabilizes misfoldedproteins including preeclampsia- and Alzheimer’s-associated amyloid beta peptide Published In Proceedings of the National Academy of Sciences of USA
2019	Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies? Published In Journal of Clinical Pathology
2019	Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma Published In Journal of Investigative Dermatology
2019	Paracrine recruitment and activation of fibroblasts by c-Myc expressing breast epithelial cells through the IGFs/IGF-1R axis Published In International Journal of Cancer
2019	The urokinase plasminogen activation system in rheumatoid arthritis: Pathophysiological roles and prospective therapeutic targets Published In Current Drug Targets
2018	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer Published In Journal of Medicinal Chemistry
2018	Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma Published In Modern Pathology
2018	Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer Published In World Journal of Gastroenterology
2018	Quantification of ligand density and stoichiometry on the surface of liposomes using single-molecule fluorescence imaging Published In Journal of Controlled Release
2018	Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Published In Clinical Colorectal Cancer
2018	Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities Published In Journal of Controlled Release
2017	A first look at the genomic landscape of non-metastatic cutaneous squamous cell carcinoma Published In Pathology
2017	Amorphous protein aggregates stimulate plasminogen activation, leading to release of cytotoxic fragments that are clients for extracellular chaperones Published In Journal of Biological Chemistry
2017	Deflexifol (a novel formulation of 5FU): Pharmacokinetics in a phase 1 trial in comparison to 5FU. Published In Journal of Clinical Oncology
2017	Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment. Published In Journal of Clinical Oncology
2017	PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma Published In Pathology
2017	Phase 1 study of infusional or bolus deflexifol (a novel formulation of 5FU, folinic acid, and cyclodextrin) after failure of standard treatment. Published In Journal of Clinical Oncology
2017	Probing the pharmacokinetics of cucurbit[7, 8 and 10]uril: and a dinuclear ruthenium antimicrobial complex encapsulated in cucurbit[10]uril Published In Organic and Biomolecular Chemistry
2017	RNA sequencing of metastatic cutaneous SCC with nano-string: preliminary results Published In Pathology
2017	Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets Published In Head and Neck
2017	SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer Published In Oncogene
2017	Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients Published In BMC Cancer
2017	The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis Published In Oncotarget
2017	p16 expression in cutaneous squamous cell carcinoma (cSCC) of the head and neck Published In Pathology
2017	p16 expression in cutaneous squamous cell carcinoma of the head and neck is not associated with integration of high risk HPV DNA or prognosis Published In Pathology
2016	5′-substituted amiloride derivatives as allosteric modulators binding in the sodium ion pocket of the adenosine A_2A receptor Published In Journal of Medicinal Chemistry
2016	A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Published In Investigational new drugs
2016	A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2016	Circulating tumour cells in regionally metastatic cutaneous squamous cell carcinoma: a pilot study Published In Oncotarget
2016	Gastric cancer stem cells: evidence, potential markers, and clinical implications Published In Journal of Gastroenterology
2016	N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell lines Published In Heliyon
2016	PZP and PAI-2: structurally-diverse, functionally similar pregnancy proteins? Published In The International Journal of Biochemistry and Cell Biology
2016	Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors Published In Bioorganic and Medicinal Chemistry Letters
2015	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. Published In Investigational new drugs
2015	Erratum to: Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery Published In Pharmaceutical Research
2015	HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer Published In Oncoscience
2015	Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery Published In Pharmaceutical Research
2015	Selecting Australian marine macroalgae based on the fatty acid composition and anti-inflammatory activity Published In Journal of Applied Phycology
2015	Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers Published In Cancer Research
2015	SerpinB2 (PAI-2) modulates proteostasis via binding misfolded proteins and promotion of cytoprotective inclusion formation Published In PLoS One
2015	Therapeutic drug monitoring for cancer patients receiving chemotherapy Published In Asia Pacific Journal of Clinical Oncology
2014	Fgfr Inhibitor and Chemotherapy in Gastric Cancer (Facing): Phase I Results from an Ecmc Combinations Alliance Phase I/II Trial of Azd4547 in Combination with Cisplatin and Capecitabine (Cx) Published In Annals of Oncology
2014	Plasmin(ogen) acquisition by group A Streptococcus protects against C3b-mediated neutrophil killing Published In Journal of Innate Immunity
2014	Preliminary Azd9291 Western and Asian Clinical Pharmacokinetics (Pk) in Patients (Pts) and Healthy Volunteers (Hv): Implications for Formulation, Dose and Dosing Frequency in Pivotal Clinical Studies Published In Annals of Oncology
2014	Updated Safety and Efficacy from a Phase I Study of Azd9291 in Patients (Pts) with Egfr-Tki-Resistant Non-Small Cell Lung Cancer (Nsclc) Published In Annals of Oncology
2013	A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection Published In PLoS Pathogens
2013	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. Published In British journal of cancer
2013	Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communication. Published In Journal of pharmaceutical and biomedical analysis
2013	Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice Published In Anticancer Research: international journal of cancer research and treatment
2013	The antiangiogenic properties of sulfated β-cyclodextrins in anticancer formulations incorporating 5-fluorouracil Published In Anti-Cancer Drugs: international journal on anti-cancer agents
2012	32 Circulating Tumour Cells, Utility Beyond Prognosis? Published In European Journal of Cancer
2012	610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma Published In European Journal of Cancer
2012	613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors Published In European Journal of Cancer
2012	Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor Published In Cancer Letters
2012	Bacterial plasminogen receptors: mediators of a multifaceted relationship Published In BioMed Research International
2012	ChemInform Abstract: Synthesis and Preliminary Evaluation of Amiloride Analogues as Inhibitors of the Urokinase‐Type Plasminogen Activator (uPA). Published In ChemInform
2012	Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms Published In Nuclear Medicine and Biology
2012	Gelapin, a degradable genipin cross-linked gelatin hydrogel Published In RSC Advances: an international journal to further the chemical sciences
2012	Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2012	Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Published In British journal of cancer
2012	Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Published In British journal of cancer
2012	Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2- diones, pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives Published In Tetrahedron: the international journal for the rapid publication of full original research papers and critical reviews in organic chemistr
2012	Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-Alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth Published In Current Cancer Drug Targets
2011	Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty? Published In International Journal of Cancer
2011	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Published In British journal of cancer
2011	Dependence on Endocytic Receptor Binding via a Minimal Binding Motif Underlies the Differential Prognostic Profiles of SerpinE1 and SerpinB2 in Cancer Published In Journal of Biological Chemistry
2011	Editorial: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy Published In Current Drug Targets
2011	Forty Years Later and the Role of Plasminogen Activator Inhibitor Type 2/SERPINB2 Is Still an Enigma Published In Seminars in Thrombosis and Hemostasis
2011	In vivo pharmacokinetics of radioiodinated urokinase plasminogen activator (UPA) inhibitors for imaging metastatic cancer Published In Internal Medicine Journal
2011	Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: implications for cellular proteolysis and adhesion in cancer Published In Cancer Letters
2011	Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2011	Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles Published In Anti-Cancer Drugs: international journal on anti-cancer agents
2011	Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand Published In Bioorganic and Medicinal Chemistry
2011	Synthesis and hydrolytic evaluation of acid-labile imine-linked cytoxic isatin model systems Published In Bioorganic and Medicinal Chemistry
2011	Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA) Published In Bioorganic and Medicinal Chemistry Letters
2010	A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. Published In Journal of Clinical Oncology
2010	A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. Published In British journal of cancer
2010	Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). Published In Journal of Clinical Oncology
2010	Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Published In The HUGO journal
2010	Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes Published In Thrombosis and Haemostasis
2010	Effects on human plasminogen conformation and activation rate caused by interaction with VEK-30, a peptide derived from the group A streptococcal M-like protein (PAM) Published In BBA: Proteins and Proteomics
2010	Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2010	P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells Published In BBA: General Subjects
2010	Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer. Published In International journal of clinical pharmacology and therapeutics
2010	Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2010	Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro Published In Bioorganic and Medicinal Chemistry Letters
2010	SerpinB2 Published In AfCS-Nature Molecule Pages
2009	A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Published In Cancer chemotherapy and pharmacology
2009	A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Published In British journal of cancer
2009	Conformational rearrangements of plasminogen activator inhibitor type 2 Published In Cellular and Molecular Life Sciences
2009	Cytotoxic and anticancer activities of Isatin and its derivatives: a comprehensive review from 2000-2008 Published In Anti-Cancer Agents in Medicinal Chemistry
2009	Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Published In British journal of cancer
2009	Detection of EGFR and KRAS mutations in circulating free DNA in patients with operable non small cell lung cancer (NSCLC) Published In Lung Cancer
2009	Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate Published In Anti-Cancer Drugs: international journal on anti-cancer agents
2009	Erratum: A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer Published In British Journal of Cancer
2009	Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): A novel paradigm in clinical drug development Published In Journal of Clinical Oncology
2009	O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Published In British journal of cancer
2009	PH-triggered release of potent isatin-derived cytotoxins conjugated to the tumour targeting protein PAI-2 Published In Annals of Oncology
2009	Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies Published In Journal of Clinical Oncology
2009	Synthesis and in vitro anticancer activity of a targeted plasminogen activator inhabitator type II (PAI-2) cytotoxin conjugate Published In Annals of Oncology
2009	Synthesis and in vitro anticancer activity of a targeted plasminogen activator inhibitor type II (PAI-2) cytotoxin conjugate Published In Annals of Oncology
2009	The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity Published In BMC Biotechnology
2008	364 POSTER Obatoclax in SCLC: preclincal evaluation of a BH3 mimetic Published In European Journal of Cancer Supplements
2008	A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours Published In Journal of Clinical Oncology
2008	A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients Published In Journal of Clinical Oncology
2008	A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Published In British journal of cancer
2008	Allelic variants of strepokinase from Streptococcus pyogenes display functional differences in plasminogen activation Published In The FASEB Journal
2008	Biomarker method validation in anticancer drug development. Published In British journal of pharmacology
2008	Biomarkers of apoptosis. Published In British journal of cancer
2008	First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin Published In Journal of Clinical Oncology
2008	N-Phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents Published In Bioorganic and Medicinal Chemistry
2008	Optimisation of circulating biomarkers of cell death for routine clinical use. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2008	Peptides and small molecules targeting the plasminogen activation system: Towards prophylactic anti-metastasis drugs for breast cancer Published In Recent Patents on Anti-Cancer Drug Discovery
2008	Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions Published In Thrombosis and Haemostasis
2008	Revisiting the biological roles of PAI2 (SERPINB2) in cancer Published In Nature Reviews Cancer
2007	6587 POSTER A phase IB, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 study Published In European Journal of Cancer Supplements
2007	A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells Published In Biochemical Journal
2007	An investigation into the Cytotoxicity and mode of action of some Novel N-Alkyl-Substituted Isatins Published In Journal of Medicinal Chemistry
2007	Corrigendum to "In vitro cytotoxicity evaluation of some substituted isatin derivatives" [Bioorg. Med. Chem. 15 (2007) 931-938] (DOI:10.1016/j.bmc.2006.10.035) Published In Bioorganic and Medicinal Chemistry
2007	Final results of a phase I clinical trial of the bioreductive drug RH1 Published In Journal of Clinical Oncology
2007	IAPs as a target for anticancer therapy. Published In Current cancer drug targets
2007	In vitro cytotoxicity evaluation of some substituted isatin derivatives Published In Bioorganic and Medicinal Chemistry
2007	P59 Building a quality assurance (QA) system that is fit for purpose in an academic laboratory Published In European Journal of Cancer Supplements
2007	Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity Published In Breast Cancer Research
2007	Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma Published In Molecular Cancer Therapeutics
2007	Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Published In Cancer chemotherapy and pharmacology
2007	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Published In Annals of oncology : official journal of the European Society for Medical Oncology
2007	The plasminogen-binding group A streptococcal M protein-related protein Prp binds plasminogen via arginine and histidine residues Published In Journal of Bacteriology
2007	Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial. Published In Cancer chemotherapy and pharmacology
2006	143 POSTER Comparison of cell death ELISAs applied as potential surrogate biomarkers in the clinical evalution of AEG35156 (XIAP antisense) Published In European Journal of Cancer Supplements
2006	221 A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma Published In Lung Cancer
2006	427 POSTER Preclinical development of xiapuradamib therapy for lung cancer Published In European Journal of Cancer Supplements
2006	A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors Published In Journal of Clinical Oncology
2006	A structural basis for differential cell signaling initiated by PAI-1 and PAI-2: Implications for Metastatic Potential Published In JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2006	Assessment of known/potential binding sites in the PAI-2 CD-loop for interaction with annexin II and endocytosis receptors Published In JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2006	Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Published In British journal of cancer
2006	Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Published In British journal of cancer
2006	SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study Published In Journal of Clinical Oncology
2006	The maintenance of high affinity plasminogen binding by PAM variants from group A streptococci is mediated by both a1 and a2 repeat domains and is not dependent on lysine residues Published In JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2006	ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial Published In Journal of Clinical Oncology
2005	A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. Published In European journal of cancer (Oxford, England : 1990)
2005	O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study Published In Lung Cancer
2005	Targeted antitumour therapy--future perspectives. Published In British journal of cancer
2005	The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results Published In Journal of Clinical Oncology
2005	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Published In British journal of cancer
2005	Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Published In British journal of cancer
2004	453 Validation of pharmacodynamic assays to determine the clinical effect of an antisense to the XIAP inhibitor of apoptosis Published In European Journal of Cancer Supplements
2004	494 Preliminary results from a phase I clinical trial of the bioreductive drug, RH1 Published In European Journal of Cancer Supplements
2004	A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus Published In Journal of Clinical Oncology
2004	A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus Published In Journal of Clinical Oncology
2004	Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC) Published In Journal of Clinical Oncology
2004	Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC) Published In Journal of Clinical Oncology
2004	DT-diaphorase: a target for new anticancer drugs. Published In Cancer treatment reviews
2004	Epidermal growth factor receptor tyrosine kinase inhibitors. Published In British journal of cancer
2004	Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Published In British journal of cancer
2003	Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Published In Lung cancer (Amsterdam, Netherlands)
2003	Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. Published In Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2002	Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Published In Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2001	56. In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2 Published In Nuclear Medicine Communications
2001	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Published In British journal of cancer
2001	Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Published In Critical reviews in oncology/hematology
2001	Characterisation of co-polymer targeting of doxorubicin and its iodinated conjugate in tumour models Published In Journal of Labelled Compounds and Radiopharmaceuticals
2001	PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study Published In European Journal of Cancer
2001	Preparation of an I‐124 labelled doxorubicin conjugate for in vivo assessment of polymer targeted anticancer therapy Published In Journal of Labelled Compounds and Radiopharmaceuticals
2000	A possible mechanism for the enhanced activation of plasminogen on malignant breast cancer cells Published In Fibrinolysis and Proteolysis
2000	Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours. Published In British journal of cancer
2000	Phase II study of Exatecan Mesylate (DX-8951f) in advanced NSCLC Published In Lung Cancer
2000	Phase II study of oral topotecan in advanced non-small cell lung cancer. Published In Clinical cancer research : an official journal of the American Association for Cancer Research
2000	Plasminogen binding and activation during late-stage cell death Published In Fibrinolysis and Proteolysis
2000	Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1999	Phase II study results on safety and efficacy of CAELYX® (DOXIL®) in combination with paclitaxel in the treatment of metastatic breast cancer Published In European Journal of Cancer
1998	Increased plasminogen binding is associated with metastatic breast cancer cells: Differential expression of plasminogen binding proteins Published In British Journal of Cancer
1998	Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control and tumour xenograft-bearing mice Published In Fibrinolysis and Proteolysis
1998	Rapid auto-catalytic processing of Gluplasminogen occurs on malignant breast cancer cell-surfaces Published In Fibrinolysis and Proteolysis
1997	195 Lysine-dependant Glu-Plasminogen binding to α-enolase induces conformational changes resulting in higher affinity interactions Published In Fibrinolysis and Proteolysis
1997	197 Do plasminogen receptors play a role in breast cancer malignancy? Published In Fibrinolysis and Proteolysis
1997	Central venous catheter placement: extending the role of the nurse. Published In Journal of the Royal College of Physicians of London
1997	Do plasminogen receptors play a role in breast cancer malignancy? Published In Fibrinolysis and Proteolysis
1997	Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Published In Seminars in oncology
1997	Lysine-dependant glu-plasminogen binding to a-enolase induces conformational changes resulting in higher affinity interactions Published In Fibrinolysis and Proteolysis
1997	Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma Published In EUROPEAN JOURNAL OF CANCER
1997	Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. Published In European journal of cancer (Oxford, England : 1990)
1997	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Published In European journal of cancer (Oxford, England : 1990)
1997	Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. Published In Seminars in oncology
1997	The human ENO1 gene product (recombinant human α-enolase) displays characteristics required for a plasminogen binding protein Published In Biochimica et Biophysica Acta - Protein Structure and Molecular Enzymology
1997	Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. Published In Journal of clinical oncology : official journal of the American Society of Clinical Oncology
1996	A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1996	Liposomal drug delivery. Published In Cancer treatment reviews
1995	1058 A phase II evaluation of bone marrow protection by ethyol® (Amifostine)(Am) in patients with non-small cell lung cancer (NSCLC) treated with carboplatin(c) Published In European Journal of Cancer
1995	Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Published In British journal of cancer
1995	Chemotherapy in non-small cell lung cancer. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1995	Gnot1, a member of a new homeobox gene subfamily, is expressed in a dynamic, region-specific domain along the proximodistal axis of the developing limb Published In Mechanisms of Development
1995	The importance of dose and schedule in chemotherapy for small cell lung cancer. Published In Anti-cancer drugs
1995	The organizer-associated chick homeobox gene, Gnot1, is expressed before gastrulation and regulated synergistically by activin and retinoic acid Published In Developmental Biology
1995	VAD chemotherapy as remission induction for multiple myeloma. Published In British journal of cancer
1994	A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer. Published In British journal of cancer
1994	Acute lymphoblastic leukaemia following Hodgkin's disease is associated with a good prognosis. Published In British journal of haematology
1994	Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1994	Effects of estrogens on human melanocytes in vitro Published In Journal of Steroid Biochemistry and Molecular Biology
1994	Population and Bayesian pharmacokinetics in oncology. Published In Clinical oncology (Royal College of Radiologists (Great Britain))
1994	Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresis. Published In Bone marrow transplantation
1994	Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1993	A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1993	Cutaneous infection with Rhizopus oryzae and Aspergillus niger following bone marrow transplantation. Published In The Journal of hospital infection
1993	Selection of optimal intensive induction chemotherapy preceding high-dose consolidation chemotherapy for advanced breast cancer and investigation of the optimal time for peripheral blood progenitor cell (PBSC) collection Published In The Breast
1992	Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma. Published In European journal of cancer (Oxford, England : 1990)
1991	An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1991	Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. Published In Journal of clinical oncology : official journal of the American Society of Clinical Oncology
1991	Post consolidation therapy for adult patients with acute myeloid leukaemia. Published In British journal of haematology
1990	Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients. Published In The Journal of hospital infection
1990	Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Published In Annals of oncology : official journal of the European Society for Medical Oncology
1990	Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. Published In European journal of cancer (Oxford, England : 1990)
1988	Extracellular matrix modulates the function of human melanocytes but not melanoma cells Published In Journal of Cellular Physiology
1988	Human melanocytes as a target tissue for hormones: In vitro studies with 1α-25, dihydroxyvitamin D3, α-melanocyte stimulating hormone, and beta-estradiol Published In Journal of Investigative Dermatology
1988	Human melanoma cells: Functional modulation by calciotropic hormones Published In Journal of Investigative Dermatology

Chapter

Year	Title
2010	Inhibitors of the Plasminogen Activation System - Promising New Agents for Suppressing Breat Cancer Metastasis Published In Frontiers in Anti-Cancer Drug Discovery
2007	Gene expression and tagging of Streptococcal proteins Published In Molecular Biology of Streptococci Publisher Wymondham

Conference Paper

Year	Title
2021	Improving delivery of amiloride analogues as uPA selective inhibitors for use in metastatic disease Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	Inhibition of focal adhesion kinase in cutaneous squamous cell carcinoma Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	Non-coding and coding genomic mutational drivers of metastatic cutaneous squamous cell carcinoma Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	Targeting the Urokinase Plasminogen Activator Pathway in Combination With Chemotherapy Inhibits Pancreatic Cancer Progression Published In PANCREAS
2021	Targeting the urokinase plasminogen activator pathway inhibits pancreatic cancer progression Published In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
2021	The potential of panel-based gene expression analysis in the identification of head and neck cutaneous squamous cell carcinoma with high risk of lymph node metastasis Published In ORAL ONCOLOGY
2021	The role of urokinase plasminogen activator receptor in HNcSCC progression and metastasis Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	Tracking circulating tumour DNA in patients with resectable gastroesophageal cancer Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2021	cMet signalling affects the invasive capacity of a gastric cancer cell circulating tumour cell line Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2018	Amiloride Analogues as Inhibitors of Human Urokinase Plasminogen Activator and Anti-Pancreatic Cancer Agents Published In PANCREAS
2018	Cancer stem cell markers in metastatic gastroesophageal adenocarcinoma Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2018	Comparison of Clinically Relevant Somatic Mutations in Primary and Metastatic Head and Neck Cutaneous Squamous Cell Carcinoma Published In MODERN PATHOLOGY
2018	Drug and radio sensitivity profile of a primary CTC cell line derived from a patient with metastatic neuroendocrine tumour of the distal oesophagus Published In ESMO Open
2018	Impact of rural and remoteness on overall survival in Australian patients with stage I-III colorectal cancer Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2018	Somatic Mutations in Head and Neck Cutaneous Squamous Cell Carcinoma Published In MODERN PATHOLOGY
2017	A First Look at the Genomic Landscape of Non-Metastatic Cutaneous Squamous Cell Carcinoma Published In LABORATORY INVESTIGATION
2017	PD-L1 Expression Predicts Improved Disease Free Survival in High Risk Head and Neck Cutaneous Squamous Cell Carcinoma Published In LABORATORY INVESTIGATION
2017	p16 Expression in Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck Published In LABORATORY INVESTIGATION
2016	Adjuvant chemotherapy for stage III colorectal cancer in the elderly Published In ANNALS OF ONCOLOGY
2016	BIOBANKING AT A REGIONAL TERTIARY HOSPITAL: AN INITIAL EXPERIENCE AND IDENTIFICATION OF BARRIERS TO PATIENT CONSENT Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2016	EXPRESSION OF UROKINASE PLASMINOGEN ACTIVATION SYSTEM IN PRIMARY GASTRO-ESOPHAGEAL ADENOCARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2016	PHARMACOKINETICS OF A NOVEL FORMULATION OF 5-FLUOROURACIL (5FU) AND LEUCOVORIN (LV): (DEFLEXIFOL) IN A PHASE I TRIAL Published In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2011	Selective Release of Potent N-Alkylisatin Based Cytotoxins via Hydrolysis of pH Sensitive Imine Linkers Published In 27th International Symposium on the Chemistry of Natural Products and the 7th International Conference on Biodiversity (ISCNP-27 & ICOB-7)
2010	Selective release of potent N-alkylisatin based cytotoxins via hydrolysis of pH sensitive imine linkers Published In 2010 International Chemical Congress of Pacific Basin Societies
2007	The pharmacokinetic and tolerability profile of once-daily oral ZD4054 in Japanese and Caucasian patients with hormone-refractory prostate cancer Published In EJC SUPPLEMENTS
2001	In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labeled-plasminogen activator inhibitor type 2 Published In EUROPEAN JOURNAL OF NUCLEAR MEDICINE
1993	Limb-type differences in expression domains of certain chick Hox-4 genes and relationship to pattern modification for flight. Published In Progress in clinical and biological research

Investigator On

Year	Title
2020 - 2023	Cutaneous Squamous Cell Carcinoma: defining prognostic markers of metastasis Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Ideas Grant
2014 - 2021	Centre for Oncology Education and Research Translation (CONCERT) Awarded by: Cancer Institute NSW Funding Scheme: Translational Cancer Research Centre
2020	Reducing the Morbidity of Head and Neck Cancer Treatment Awarded by: Cancer Institute NSW Funding Scheme: Translational Program Grant (TPG)
2016 - 2019	Repurposing Amiloride into Breast Cancer Drugs with a Dual-Targeting Mechanism Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Project Grant
2014	COUNTESS 11 FL Cell Counter and Qubit Quant Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2013	Neon Transfection System: Workstation for transfer of genetic material into hard-to-work-with cells Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2012	Optimisation of PAI-2 forms for non-invasive PET imaging of malignant tumours Awarded by: Australian Institute of Nuclear Science and Engineering (AINSE) Funding Scheme: Research Awards
2011	Regional facility for macomolecular X-ray crystallography Awarded by: Australian Research Council (ARC) Funding Scheme: Linkage Infrastructure Equipment & Facilities (LIEF)
2009	Regional facility for real time analysis of molecular interactions Awarded by: Australian Research Council (ARC) Funding Scheme: Linkage Infrastructure Equipment & Facilities (LIEF)
2008	Optimised delivery of chemotherapy for solid tumours Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Development Grant
2007	Avestin EmulsiFlex TM-C5 Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2007	Unified model for group A streptococcal invasive disease initiation Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Project Grant
	Contributions to Leica Dmi8 microscope Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
	GoBlot machines and Leica Objective Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
	Lumenera Infinity 2-5 microscope colour camera Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
	Novel uPA-targeting small molecules for the treatment of rheumatoid arthritis Awarded by: Arthritis Australia Funding Scheme: Grant-in-Aid
	Unravelling genetic markers of progression and metastases in head and neck cutaneous squamous cell carcinoma Awarded by: Australian and New Zealand Head and Neck Cancer Society Research Foundation Funding Scheme: Research Grant

Potential Supervision Topics

Cutaneous Squamous Cell Carcinoma: Defining Prognostic Markers of Metastasis

Advisees

Graduate Advising Relationship

Degree	Research Title	Advisee
Doctor of Philosophy	Bismuth-NSAIDs as Colorectal Cancer Chemopreventatives	Oliver, Tara
Doctor of Philosophy	Investigations of the roles of pregnancy zone protein (PZP) and plasminogen activator inhibitor type-2 (PAl-2) in extracellular proteostasis	Cater, Jordan
Doctor of Philosophy	Pharmacological Profiling of Amiloride Analogues as Inhibitors of the Urokinase Plasminogen Activation System in Pancreatic Ductal Adenocarcinoma	Kumar, Ashna
Doctor of Philosophy	Molecular and Clinical Biomarker assessment of gastric cancer	Tincknell, Gary
Doctor of Philosophy	Metastatic cutaneous squamous cell carcinoma (cSCC): development of 3- dimensional patient-derived cultures for functional genomics and drug response profiling.	Genenger, Benjamin
Doctor of Philosophy	Localized delivery of chemotherapy and Immunotherapy for Triple-negative breast cancer.	Minaei, Elahe

Education And Training

Ph.D., University of Sydney 1990
B.Sc. in Biochemistry, University of New South Wales, Hons 1985

Awards And Honors

Vice-Chancellorâs Award for Excellence in Research Supervision , conferred by University of Wollongong, 2007
Gessellschaft fur Biotechnologische Forschung (GBF) , 2004
Biomedical Postgraduate Scholarship, conferred by NHMRC, 1989
Cancer Institute NSW Career Development and Support Fellowship , conferred by Cancer Institute NSW, 2005 - 2008
Fogarty Visiting Post-Doctoral Fellowship, conferred by NIH, 1990 - 1992
Australian National Heart Foundation Vacation Scholarships, conferred by Australian National Heart Foundation, 1983 - 1984

Orcid Id

http://orcid.org/0000-0002-5570-9645 (confirmed)

Web Of Science Researcher Id

A-6324-2008

Scopus Id

7005465112

Overview

Top Publications

Research Areas

Research Overview

Affiliation

Head Of

Member Of

Has Collaborator

Clinical Activities

Publications

Selected Publications

Journal Article

Chapter

Conference Paper

Funding

Investigator On

Supervision

Potential Supervision Topics

Advisees

Graduate Advising Relationship

Background

Education And Training

Awards And Honors

Identity

Orcid Id

Web Of Science Researcher Id

Scopus Id

Overview

Top Publications

Research Areas

Research Overview

Affiliation

Head Of

Member Of

Has Collaborator

Clinical Activities

Publications

Selected Publications

Journal Article

Chapter

Conference Paper

Funding

Investigator On

Supervision

Potential Supervision Topics

Advisees

Graduate Advising Relationship

Background

Education And Training

Awards And Honors

Identity

Orcid Id

Web Of Science Researcher Id

Scopus Id

Visualisations

Research Areas